Crinetics Pharmaceuticals, Inc.
DE ˙ DB ˙ US22663K1079
27,79 € ↑0,30 (1,09%)
2026-06-04
DEL PRIS
SecurityDE:6Z4 / Crinetics Pharmaceuticals, Inc.
InstitutionState Street Corp
Latest Disclosed Ownership2,838,484 shares
Ownership 3.60%
State Street Corp ownership in 6Z4 / Crinetics Pharmaceuticals, Inc.

2024-10-17 - State Street Corp has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 2,838,484 shares of Crinetics Pharmaceuticals, Inc. (DE:6Z4). This represents 3.6 percent ownership of the company. In their previous filing dated 2024-01-24 , State Street Corp had reported owning 3,563,736 shares, indicating a decrease of -20.35 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2024-10-17 2024-10-17 13G/A 3,563,736 2,838,484 -20.35 3.60 -32.58
2024-01-24 2024-01-24 13G 3,563,736 5.34

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 2,403,046 241,668 11.18 87,279 -13.25 0.0030
2026-02-13 2025-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 2,161,378 -46,329 -2.10 100,612 9.42 0.0034
2025-11-14 2025-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 2,207,707 -1,016,599 -31.53 91,951 -0.84 0.0032
2025-08-14 2025-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 3,224,306 -58,969 -1.80 92,731 -15.79 0.0035
2025-05-15 2025-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 3,283,275 292,437 9.78 110,121 -27.99 0.0045
2025-02-14 2024-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 2,990,838 152,354 5.37 152,922 5.43 0.0060
2024-11-14 2024-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 2,838,484 25,561 0.91 145,047 15.13 0.0059
2024-08-14 2024-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 2,812,923 -442,330 -13.59 125,991 -17.32 0.0055
2024-05-15 2024-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 3,255,253 -308,483 -8.66 152,378 20.17 0.0068
2024-02-14 2023-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 3,563,736 711,016 24.92 126,798 49.46 0.0062
2023-11-14 2023-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 2,852,720 614,985 27.48 84,840 110.40 0.0047
2023-08-14 2023-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 2,237,735 18,941 0.85 40,324 13.16 0.0021
2023-05-15 2023-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 2,218,794 214,010 10.67 35,634 -2.87 0.0020
2023-05-15 2022-12-31 13F/A-99 CRINETICS PHARMACEUTICALS IN COM 22663K107 2,004,784 196,119 10.84 36,688 3.28 0.0022
2023-05-15 2022-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 2,004,784 196,119 36,688 0.0022
2022-11-15 2022-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 1,808,665 47,820 2.72 35,522 8.17 0.0022
2022-08-15 2022-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 1,760,845 60,166 3.54 32,840 -12.03 0.0020
2022-05-16 2022-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 1,700,679 400,305 30.78 37,330 1.04 0.0018
2022-02-14 2021-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 1,300,374 184,515 16.54 36,944 57.28 0.0018
2021-11-15 2021-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 1,115,859 569,427 104.21 23,489 128.05 0.0012
2021-08-16 2021-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 546,432 73,871 15.63 10,300 42.64 0.0005
2021-07-09 2021-03-31 13F/A-1 CRINETICS PHARMACEUTICALS IN COM 22663K107 472,561 -8,238 -1.71 7,221 6.44 0.0004
2021-05-17 2021-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 472,561 -8,238 7,221 0.0004
2021-02-16 2020-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 480,799 37,024 8.34 6,784 -2.44 0.0004
2020-11-10 2020-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 443,775 24,800 5.92 6,954 -5.26 0.0005
2020-08-14 2020-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 418,975 194,481 86.63 7,340 122.42 0.0005
2020-06-19 2020-03-31 13F/A-1 CRINETICS PHARMACEUTICALS IN COM 22663K107 224,494 -2,107 -0.93 3,300 -41.95 0.0003
2020-05-11 2020-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 224,494 -2,107 3,300 289.8064
2020-02-06 2019-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 226,601 20,305 9.84 5,685 83.21 0.0004
2019-11-14 2019-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 206,296 2,668 1.31 3,103 -39.05 0.0002
2019-08-14 2019-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 203,628 98,229 93.20 5,091 112.21 0.0004
2019-05-15 2019-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 105,399 2,251 2.18 2,399 -22.44 0.0002
2019-02-12 2018-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 103,148 26,769 35.05 3,093 41.30 0.0003
2018-11-09 2018-09-30 13F CRINETICS PHARMCTCL Common Stock 22663K107 76,379 76,379 2,189 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.